Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Glenmark Pharmaceuticals Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Glenmark Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Primary Myelofibrosis Indication Strategy Report 2026: JAK2, BRD4, Trials and Deal Outlook
20 July 2026
A 2026 primary myelofibrosis strategy report covering disease burden, JAK2 and BRD4 biology, clinical competition, deal signals and portfolio positioning.
Latest Hotspot
8 min read
Follicular Lymphoma Indication Strategy Report 2026: CD20, EZH2, Trials and Deal Outlook
20 July 2026
A 2026 follicular lymphoma strategy report covering disease burden, CD20 and EZH2 biology, clinical competition, transaction signals and portfolio positioning.
Latest Hotspot
8 min read
Polycythemia Vera Indication Strategy Report 2026: JAK2, Hepcidin, Trials and Deal Outlook
20 July 2026
A 2026 polycythemia vera strategy report covering disease burden, JAK2 and hepcidin biology, clinical competition, transaction signals and portfolio positioning.
Latest Hotspot
8 min read
Myelodysplastic Syndromes Indication Strategy Report 2026: BCL-2, p53, Trials and Deal Outlook
20 July 2026
A 2026 myelodysplastic syndromes strategy report covering disease burden, BCL-2 and p53 biology, clinical competition, transaction signals and portfolio positioning.
Latest Hotspot
8 min read
Essential Thrombocythemia Indication Strategy Report 2026: JAK2, CALR, Trials and Deal Outlook
20 July 2026
A 2026 essential thrombocythemia strategy report covering disease burden, JAK2 and CALR biology, clinical competition, transaction signals and portfolio positioning.
Latest Hotspot
8 min read
Chronic Lymphocytic Leukemia Indication Strategy Report 2026: BTK, BCL-2, Trials and Deal Outlook
20 July 2026
A 2026 chronic lymphocytic leukemia strategy report covering disease burden, BTK and BCL-2 biology, clinical competition, deal activity and portfolio positioning.
Latest Hotspot
8 min read
Hodgkin Lymphoma Indication Strategy Report 2026: PD-1, CD30, Trials and Deal Outlook
20 July 2026
A 2026 Hodgkin lymphoma strategy report covering disease burden, PD-1 and CD30 biology, clinical competition, transaction signals and portfolio positioning.
Latest Hotspot
8 min read
Zydus Lifesciences Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Zydus Lifesciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Lupin Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Lupin 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Cipla Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Cipla 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Sun Pharmaceutical Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Sun Pharmaceutical 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.